.Nature Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a mean follow-up of 11 months, individuals along with metastatic intestinal lumps who got biomarker-matched therapies based upon distributing growth DNA profiling presented a greater scientific benefit than those receiving unrivaled treatment.